Viva Biotech Holdings Cash Flow Conversion Efficiency
Viva Biotech Holdings cash flow conversion efficiency. Based on the latest financial reports, Viva Biotech Holdings (VB0) has a cash flow conversion efficiency ratio of 0.044x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€158.72 Million ≈ $185.57 Million USD) by net assets (€3.64 Billion ≈ $4.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Viva Biotech Holdings (2016–2024)
Cash flow conversion efficiency of Viva Biotech Holdings from 2016 to 2024. This chart illustrates how Viva Biotech Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VB0 stock price for real-time trading data and today's change.
Viva Biotech Holdings Cash Flow Conversion Ratio Explained
Viva Biotech Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Viva Biotech Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viva Biotech Holdings ranked by their cash flow conversion efficiency. Also see VB0 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
0.134x |
|
Aramis SAS
PA:ARAMI
|
0.246x |
|
JinGuan Electric Co Ltd
SHG:688517
|
0.020x |
|
Singer Thailand Public Company Limited
BK:SINGER
|
0.001x |
|
Transcontinental Realty Investors
NYSE:TCI
|
-0.003x |
|
Teqnion AB
ST:TEQ
|
0.039x |
|
Junhe Pumps Holding Co Ltd
SHG:603617
|
0.035x |
|
Seoul Food
KO:004410
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Viva Biotech Holdings (2016–2024)
The table below shows the annual cash flow conversion efficiency of Viva Biotech Holdings from 2016 to 2024. Review Viva Biotech Holdings (VB0) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €3.82 Billion ≈ $4.46 Billion |
€373.99 Million ≈ $437.23 Million |
0.098x | -5.74% |
| 2023-12-31 | €3.69 Billion ≈ $4.31 Billion |
€383.40 Million ≈ $448.24 Million |
0.104x | -2.93% |
| 2022-12-31 | €3.60 Billion ≈ $4.21 Billion |
€386.05 Million ≈ $451.33 Million |
0.107x | +438.49% |
| 2021-12-31 | €3.91 Billion ≈ $4.58 Billion |
€77.83 Million ≈ $90.99 Million |
0.020x | +73.03% |
| 2020-12-31 | €3.76 Billion ≈ $4.39 Billion |
€43.18 Million ≈ $50.48 Million |
0.011x | -55.60% |
| 2019-12-31 | €1.78 Billion ≈ $2.08 Billion |
€46.01 Million ≈ $53.79 Million |
0.026x | -46.25% |
| 2018-12-31 | €251.44 Million ≈ $293.96 Million |
€12.11 Million ≈ $14.16 Million |
0.048x | -73.62% |
| 2017-12-31 | €152.76 Million ≈ $178.59 Million |
€27.89 Million ≈ $32.61 Million |
0.183x | -33.86% |
| 2016-12-31 | €76.50 Million ≈ $89.44 Million |
€21.12 Million ≈ $24.69 Million |
0.276x | -- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more